|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||9.74 - 10.19|
|52 Week Range||3.73 - 13.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.14|
“As ImmunoGen continues to evolve, we look to complement our existing team with outside talent with experience to accelerate our transition to a fully-integrated biotechnology company delivering innovative products to improve outcomes for cancer patients,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
Biotech stocks continued to be in the red this week, with the losses worse than what the broader market suffered. Here's a list of key events associated with biotech stocks one needs to focus on, in the ...
Investors were generally pleased with a data drop over the weekend, but it wasn't enough to keep ImmunoGen from tanking for no apparent reason on Tuesday.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II cohort assessing mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy pembrolizumab in patients with platinum-resistant epithelial ovarian cancer .
The volatile nature of biotech stocks is evident from the wild swings they experience in the wake of catalytic events, which in fact present profit-making opportunities for an astute investor. This week ...
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research Annual Meeting to be held from April 14-18, 2018 in Chicago.
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carbo ...
ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.
ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.
In this article I am going to calculate the intrinsic value of ImmunoGen Inc (NASDAQ:IMGN) using the discounted cash flows (DCF) model. If you want to learn more about thisRead More...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs, came to 10 cents per share. The results missed Wall Street expectations. ...
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today reviewed recent highlights and operating results for the quarter and year ended December 31, 2017.